EZH2: biology, disease, and structure-based drug discovery

EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. Overexpression of EZH2 has been found in a wide range of cancers, including those of the prostate and breast. In this review, we address the current understanding of the oncogenic role of EZH2, including its PRC2-dependent transcriptional repression and PRC2-independent gene activation. We also discuss the connections between EZH2 and other silencing enzymes, such as DNA methyltransferase and histone deacetylase. We comprehensively address the architecture of the PRC2 complex and the crucial roles of each subunit. Finally, we summarize new progress in developing EZH2 inhibitors, which could be a new epigenetic therapy for cancers.

[1]  Zhaohui S. Qin,et al.  Coordinated regulation of polycomb group complexes through microRNAs in cancer. , 2011, Cancer cell.

[2]  Jon R. Wilson,et al.  SET domains and histone methylation. , 2003, Current opinion in structural biology.

[3]  C. Meijer,et al.  Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. , 2001, Blood.

[4]  D. Reinberg,et al.  Role of the polycomb protein EED in the propagation of repressive histone marks , 2009, Nature.

[5]  P. Chiang.  Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. , 1998, Pharmacology & therapeutics.

[6]  Jun Liu,et al.  Cooperation between Polycomb and androgen receptor during oncogenic transformation. , 2012, Genome research.

[7]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[8]  T. Magnuson,et al.  Molecular and functional mapping of EED motifs required for PRC2-dependent histone methylation. , 2007, Journal of molecular biology.

[9]  J. Simon,et al.  Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.

[10]  A. Otte,et al.  Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation , 1999, Nature Genetics.

[11]  M. Jouvenot,et al.  Epigenetic regulation of estrogen signaling in breast cancer , 2013, Epigenetics.

[12]  Axel Imhof,et al.  Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 , 2005, Nature chemical biology.

[13]  Ruedi Aebersold,et al.  Molecular architecture of human polycomb repressive complex 2 , 2012, eLife.

[14]  E. Selker,et al.  Structural basis for the product specificity of histone lysine methyltransferases. , 2003, Molecular cell.

[15]  K. Hahn,et al.  An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. , 2013, ACS chemical biology.

[16]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Brian C. Smith,et al.  Chemical mechanisms of histone lysine and arginine modifications. , 2009, Biochimica et biophysica acta.

[18]  Paul Tempst,et al.  Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. , 2004, Molecular cell.

[19]  Kristian Helin,et al.  Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity , 2004, The EMBO journal.

[20]  M. Thompson,et al.  Catalytic Roles for Carbon-Oxygen Hydrogen Bonding in SET Domain Lysine Methyltransferases* , 2006, Journal of Biological Chemistry.

[21]  Haojie Huang,et al.  Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. , 2010, Endocrinology.

[22]  Robert E Collins,et al.  Structural and sequence motifs of protein (histone) methylation enzymes. , 2005, Annual review of biophysics and biomolecular structure.

[23]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[24]  J. Snyder,et al.  Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294 , 2009, Nature Structural &Molecular Biology.

[25]  K. Hallenbeck,et al.  Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET. , 2013, The Biochemical journal.

[26]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[27]  E. Jane,et al.  The Drosophila Polycomb Group proteins ESC and E(Z) are present in a complex containing the histone-binding protein p55 and the histone deacetylase RPD3. , 2001, Development.

[28]  Jinrong Min,et al.  Structure of the SET domain histone lysine methyltransferase Clr4 , 2002, Nature Structural Biology.

[29]  A. Ventura,et al.  Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. , 2011, Cancer research.

[30]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[31]  Ming-Ming Zhou,et al.  Dimerization of a viral SET protein endows its function , 2010, Proceedings of the National Academy of Sciences.

[32]  Qiang Yu,et al.  Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells , 2009, Molecular Cancer Therapeutics.

[33]  Xiaodong Zhang,et al.  Enzymatic mechanism and product specificity of SET-domain protein lysine methyltransferases , 2008, Proceedings of the National Academy of Sciences.

[34]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[35]  E. Selker,et al.  In Vitro and in Vivo Analyses of a Phe/Tyr Switch Controlling Product Specificity of Histone Lysine Methyltransferases* , 2005, Journal of Biological Chemistry.

[36]  Yong Jiang,et al.  Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) , 2012, Proceedings of the National Academy of Sciences.

[37]  D. Ghosh,et al.  A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. , 2007, Cancer research.

[38]  Carl Wu,et al.  Drosophila NURF-55, a WD repeat protein involved in histone metabolism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Chai,et al.  Structural Basis of EZH 2 Recognition by EED , 2022 .

[40]  P. Atadja,et al.  Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation , 2012, Proceedings of the National Academy of Sciences.

[41]  Stormy J. Chamberlain,et al.  The Murine Polycomb Group Protein Eed Is Required for Global Histone H3 Lysine-27 Methylation , 2005, Current Biology.

[42]  E. Selker,et al.  Structure of the Neurospora SET Domain Protein DIM-5, a Histone H3 Lysine Methyltransferase , 2002, Cell.

[43]  T. Furuyama,et al.  The Drosophila Polycomb Group proteins ESC and E(Z) bind directly to each other and co-localize at multiple chromosomal sites. , 1998, Development.

[44]  Qiang Yu,et al.  Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage , 2011, Cell Death and Differentiation.

[45]  J. Chai,et al.  Structural basis of EZH2 recognition by EED. , 2007, Structure.

[46]  S. Shirasawa,et al.  Polycomb Group Suppressor of Zeste 12 Links Heterochromatin Protein 1α and Enhancer of Zeste 2* , 2004, Journal of Biological Chemistry.

[47]  Valérie Campagna-Slater,et al.  Structural Biology of Human H3K9 Methyltransferases , 2010, PloS one.

[48]  R. Kobayashi,et al.  Nucleosome Assembly by a Complex of CAF-1 and Acetylated Histones H3/H4 , 1996, Cell.

[49]  M. Bray,et al.  Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. , 2000, Antiviral research.

[50]  Qiang Yu,et al.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.

[51]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[52]  Yi Zhang,et al.  SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.

[53]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[54]  M. Vidal,et al.  Role of histone H2A ubiquitination in Polycomb silencing , 2004, Nature.

[55]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[57]  Maxim Nekrasov,et al.  Nucleosome binding and histone methyltransferase activity of Drosophila PRC2 , 2005, EMBO reports.

[58]  O. Elemento,et al.  EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. , 2010, Blood.

[59]  J. Mackay,et al.  Insights into Association of the NuRD Complex with FOG-1 from the Crystal Structure of an RbAp48·FOG-1 Complex , 2010, The Journal of Biological Chemistry.

[60]  F. Tie,et al.  The N Terminus of Drosophila ESC Binds Directly to Histone H3 and Is Required for E(Z)-Dependent Trimethylation of H3 Lysine 27 , 2007, Molecular and Cellular Biology.

[61]  J. Simon,et al.  Inner workings and regulatory inputs that control Polycomb repressive complex 2 , 2012, Chromosoma.

[62]  A. Bauer,et al.  Histone methylation by PRC2 is inhibited by active chromatin marks. , 2011, Molecular cell.

[63]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[64]  X. Zhao,et al.  Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity , 2013, Leukemia.

[65]  Chao Xu,et al.  Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2) , 2010, Proceedings of the National Academy of Sciences.

[66]  Karl Mechtler,et al.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.

[67]  Bradley P. Coe,et al.  EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[68]  Geoff Kelly,et al.  Structure and catalytic mechanism of the human histone methyltransferase SET7/9 , 2003, Nature.

[69]  Robert A. Copeland,et al.  Protein methyltransferases as a target class for drug discovery , 2009, Nature Reviews Drug Discovery.

[70]  R. Küppers,et al.  Hodgkin lymphoma. , 2012, The Journal of clinical investigation.

[71]  V. Thakur,et al.  Multifaceted role of EZH2 in breast and prostate tumorigenesis , 2013, Epigenetics.

[72]  Ming-Ming Zhou,et al.  Structural insights of the specificity and catalysis of a viral histone H3 lysine 27 methyltransferase. , 2006, Journal of molecular biology.

[73]  Jing Liang,et al.  Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells , 2007, Molecular and Cellular Biology.

[74]  P. Finn,et al.  Epigenetic approaches to cancer therapy. , 2004, Biochemical Society transactions.

[75]  S. Strome,et al.  Subunit Contributions to Histone Methyltransferase Activities of Fly and Worm Polycomb Group Complexes , 2005, Molecular and Cellular Biology.